{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:38:12Z","timestamp":1792636692897,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Maggie Stephens Foundation"},{"DOI":"10.13039\/501100003748","name":"Swedish Society for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An increasing proportion of the population receives immunosuppressive treatment. There is a lack of guidelines for bloodstream infections (BSIs) in this group. This study aims to provide a comprehensive analysis of the etiology and outcomes in BSI associated with underlying immunosuppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This population-based laboratory surveillance study included all positive blood cultures in southern Sweden, from 2013 through 2023. Immunosuppression was defined using diagnostic codes, medications, and laboratory data. We defined 6 categories of immunosuppression: antineoplastic treatment, neutropenia, immunosuppressant medication, organ transplants, primary immunodeficiency, and human immunodeficiency virus infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 8058 of 47 552 (16.9%) BSI episodes were associated with underlying immunosuppression. This proportion increased over time (rate ratio, 1.019 per year [95% confidence interval {CI}, 1.012\u20131.027], P &amp;lt; .001). Immunosuppression was associated with a higher degree of Enterococcus faecium (odds ratio [OR], 3.16 [95% CI, 2.63\u20133.78]) and Pseudomonas spp (OR, 2.51 [95% CI, 2.16\u20132.91]) etiology. Intrinsic cephalosporin resistance was more frequent in BSI episodes with underlying immunosuppression (OR, 1.45 [95% CI, 1.36\u20131.55]). The 30-day mortality rate was higher in BSI episodes with underlying immunosuppression, at 17.9% (1439\/8044), compared to 12.5% (4880\/39 089) in episodes without immunosuppression (OR, 1.54 [95% CI, 1.45\u20131.64]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides an updated summary of etiology and outcomes in BSI associated with immunosuppression. Underlying immunosuppression is increasingly prevalent among patients with BSI and is associated with resistance to cephalosporins and increased short-term mortality. Clinical guidelines for the management of BSI in immunosuppressed patients are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag655","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:50:07Z","timestamp":1792633807000},"source":"Crossref","is-referenced-by-count":0,"title":["Etiology and Outcomes of Bloodstream Infections by Immunosuppression Type: A Population-Based Laboratory Surveillance Study"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2951-1309","authenticated-orcid":false,"given":"Oskar","family":"Ljungquist","sequence":"first","affiliation":[{"name":"Division of Infection Medicine, Department of Clinical Sciences, Faculty of Medicine, Lund University , Lund ,","place":["Sweden"]},{"name":"Department of Infectious Diseases, Helsingborg Hospital , Helsingborg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3433-512X","authenticated-orcid":false,"given":"Fredrik","family":"Resman","sequence":"additional","affiliation":[{"name":"Clinical Infection Medicine, Department of Translational Medicine, Lund University , Malm\u00f6 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7446-463X","authenticated-orcid":false,"given":"Karl","family":"Oldberg","sequence":"additional","affiliation":[{"name":"Division of Infection Medicine, Department of Clinical Sciences, Faculty of Medicine, Lund University , Lund ,","place":["Sweden"]},{"name":"Department of Clinical Microbiology, Sk\u00e5ne University Hospital , Lund ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2778-5314","authenticated-orcid":false,"given":"Anna","family":"Bl\u00e4ckberg","sequence":"additional","affiliation":[{"name":"Division of Infection Medicine, Department of Clinical Sciences, Faculty of Medicine, Lund University , Lund ,","place":["Sweden"]},{"name":"Department of Infectious Diseases, Sk\u00e5ne University Hospital , Lund ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9240-2378","authenticated-orcid":false,"given":"Torgny","family":"Sunnerhagen","sequence":"additional","affiliation":[{"name":"Division of Infection Medicine, Department of Clinical Sciences, Faculty of Medicine, Lund University , Lund ,","place":["Sweden"]},{"name":"Department of Clinical Microbiology, Sk\u00e5ne University Hospital , Lund ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9012-2068","authenticated-orcid":false,"given":"Gustav","family":"Torisson","sequence":"additional","affiliation":[{"name":"Clinical Infection Medicine, Department of Translational Medicine, Lund University , Malm\u00f6 ,","place":["Sweden"]},{"name":"Department of Infectious Diseases, Sk\u00e5ne University Hospital , Malm\u00f6 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"2026102121500351500_ofag655-B1","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.10.2200519","article-title":"Incidence, aetiology and temporal trend of bloodstream infections in southern Sweden from 2006 to 2019: a population-based study","volume":"28","author":"Ljungquist","year":"2023","journal-title":"Euro Surveill"},{"key":"2026102121500351500_ofag655-B2","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1502893","article-title":"The increasing incidence and mortality of bacteremia in Denmark from 2010 to 2022: a population-based nationwide cohort study","volume":"12","author":"Dessau","year":"2024","journal-title":"Front Public Health"},{"key":"2026102121500351500_ofag655-B3","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3201\/eid2710.204826","article-title":"Population-based study of bloodstream infection incidence and mortality rates, Finland, 2004-2018","volume":"27","author":"Kontula","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2026102121500351500_ofag655-B4","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jama.2023.28019","article-title":"Prevalence of immunosuppression among US adults","volume":"331","author":"Martinson","year":"2024","journal-title":"JAMA"},{"key":"2026102121500351500_ofag655-B5","author":"Socialstyrelsen (National Board of Health and Welfare)"},{"key":"2026102121500351500_ofag655-B6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1127704","article-title":"Immunomodulation\u2014a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system","volume":"14","author":"Strzelec","year":"2023","journal-title":"Front Immunol"},{"key":"2026102121500351500_ofag655-B7","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.DMIH2-0026-2016","article-title":"Overview of infections in the immunocompromised host","volume":"4","author":"Dropulic","year":"2016","journal-title":"Microbiol Spectr"},{"key":"2026102121500351500_ofag655-B8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00134-020-05950-6","article-title":"Bloodstream infections in critically ill patients: an expert statement","volume":"46","author":"Timsit","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026102121500351500_ofag655-B9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cmi.2019.10.031","article-title":"Burden of bacterial bloodstream infection\u2014a brief update on epidemiology and significance of multidrug-resistant pathogens","volume":"26","author":"Kern","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2026102121500351500_ofag655-B10","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","author":"GBD 2021 Antimicrobial Resistance Collaborators","year":"2024","journal-title":"Lancet"},{"key":"2026102121500351500_ofag655-B11","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.cmi.2025.05.027","article-title":"Association of time to positivity with disease severity in bloodstream infections\u2014a population-based cohort study","volume":"31","author":"Ljungquist","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026102121500351500_ofag655-B12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/CLEP.S282475","article-title":"Adaptation of the Charlson Comorbidity Index for register-based research in Sweden","volume":"13","author":"Ludvigsson","year":"2021","journal-title":"Clin Epidemiol"},{"key":"2026102121500351500_ofag655-B13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/M18-3192","article-title":"Management of patients with fever and neutropenia through the arc of time: a narrative review","volume":"170","author":"Pizzo","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026102121500351500_ofag655-B14","author":"Swedish Association of Infectious Disease Physicians"},{"key":"2026102121500351500_ofag655-B15","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026102121500351500_ofag655-B16","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026102121500351500_ofag655-B17","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00277-019-03622-0","article-title":"Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO)","volume":"98","author":"Kochanek","year":"2019","journal-title":"Ann Hematol"},{"key":"2026102121500351500_ofag655-B18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.idh.2019.08.006","article-title":"Bloodstream infections in neutropenic patients with haematological malignancies","volume":"25","author":"Carvalho","year":"2020","journal-title":"Infect Dis Health"},{"key":"2026102121500351500_ofag655-B19","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1007\/s10238-023-01206-x","article-title":"Bloodstream infections in neutropenic and non-neutropenic patients with haematological malignancies: epidemiological trends and clinical outcomes in Queensland, Australia over the last 20 years","volume":"23","author":"Peri","year":"2023","journal-title":"Clin Exp Med"},{"key":"2026102121500351500_ofag655-B20","first-page":"786","article-title":"Listeria monocytogenes infection in a patient treated with methotrexate for rheumatoid arthritis","volume":"22","author":"McCambridge","year":"1995","journal-title":"J Rheumatol"},{"key":"2026102121500351500_ofag655-B21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2026102121500351500_ofag655-B22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2334-12-85","article-title":"The distinct category of healthcare associated bloodstream infections","volume":"12","author":"Lenz","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2026102121500351500_ofag655-B23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/1469-0691.12195","article-title":"Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe","volume":"19","author":"Goto","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2026102121500351500_ofag655-B24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijid.2018.03.022","article-title":"Bloodstream infections in cancer patients. Risk factors associated with mortality","volume":"71","author":"Islas-Mu\u00f1oz","year":"2018","journal-title":"Int J Infect Dis"},{"key":"2026102121500351500_ofag655-B25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cmi.2021.07.021","article-title":"Bacterial and fungal bloodstream infections in solid organ transplant recipients: results from a Danish cohort with nationwide follow-up","volume":"28","author":"M\u00f8ller","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026102121500351500_ofag655-B26","doi-asserted-by":"crossref","first-page":"1104.e9","DOI":"10.1016\/j.cmi.2015.07.021","article-title":"Factors influencing mortality in solid organ transplant recipients with bloodstream infection","volume":"21","author":"Oriol","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2026102121500351500_ofag655-B27","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1128\/JCM.01198-14","article-title":"Time to positivity and detection of growth in anaerobic blood culture vials predict the presence of Candida glabrata in candidemia: a two-center European cohort study","volume":"52","author":"Cobos-Trigueros","year":"2014","journal-title":"J Clin Microbiol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag655\/72260448\/ofag655.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag655\/72260448\/ofag655.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:50:11Z","timestamp":1792633811000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag655\/8965558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag655","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,29]]},"article-number":"ofag655"}}